Subscribe to RSS
Synthesis of a p38 MAP Kinase Inhibitor
R. R. Milburn et al.*
Amgen Inc, Thousand Oaks, USA
18 March 2011 (online)
The target p38 MAP kinase inhibitor is a candidate for the treatment of various inflammatory disorders, such as rheumatoid arthritis, psoriasis and Crohn’s disease. It was synthesized on a multikilogram scale in eight steps from 2,6-difluoroaniline in 38% overall yield without recourse to chromatography.